Areas of Focus
- Inflammatory diseases
- Drug discovery
- Mechanism research
Work Experience
- 1992.07-1996.08 Assistant Engineer, Changchun Institute of Biological Products
- 2004.12-2009.07 Postdoc Research Fellow, University of Georgia, Athens, USA
- 2011.03-Present Associate Professor, College of Veterinary Medicine, Jilin University
Academic Background & Achievements
- 1987.08-1992.07 Bachelor's Degree in Biochemistry, Jilin University
- 1996.09-1999.07 Master's Degree in Biochemistry and Molecular Biology, Jilin University
- 2001.09-2004.07 Doctorate in Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Publications
- Purple tea water extract blocks RANKL-induced osteoclastogenesis through modulation of Akt/GSK3β and Blimp1-Irf8 pathways, Zhang Y, Wang J, Jing C, Zhou MX, Jin W, Yan X, Hou H, Shi K,Sun WC(*), Sun L(*), 2022
- Sec-O-Glucosylhamaudol Inhibits RANKL-Induced Osteoclastogenesis by Repressing 5-LO and AKT/GSK3β Signaling, Cao J, Zhou MX, Chen X, Sun M, Wei C, Peng Q, Cheng Z(*),Sun W(*), Wang H(*), 2022
- Agrimophol suppresses RANKL-mediated osteoclastogenesis through Blimp1-Bcl6 axis and prevents inflammatory bone loss in mice, Cao J, Wang S, Wei C, Lin H, Zhang C, Gao Y, Xu Z, Cheng Z(*), Sun WC(*), Wang HB(*), 2021
- Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in MiceviaModulation of NFATc1, Hou H, Peng Q, Wang S, Zhang Y, Cao J, Deng Y, Wang Y(*), Sun WC(*), Wang HB(*), 2020
- Tatarinan T, an α-asarone-derived lignin, attenuates osteoclastogenesis induced by RANKL via the inhibition of NFATc1/c-Fos expression, Zhang Y, Wang Z, Xie X, Wang S, Wang Y, Quan G, Wang H(*), Sun WC(*), 2019
